A new trading day began on Monday, with Protara Therapeutics Inc (NASDAQ: TARA) stock price down -18.52% from the previous day of trading, before settling in for the closing price of $4.32. TARA’s price has ranged from $1.60 to $10.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 22.27%. With a float of $32.88 million, this company’s outstanding shares have now reached $35.04 million.
Let’s determine the extent of company efficiency that accounts for 33 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Protara Therapeutics Inc (TARA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Protara Therapeutics Inc is 10.58%, while institutional ownership is 79.40%. The most recent insider transaction that took place on Mar 26 ’25, was worth 96,145. In this transaction Chf Scientific Operations Off of this company sold 21,224 shares at a rate of $4.53, taking the stock ownership to the 98,861 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Officer proposed sale 21,224 for $4.55, making the entire transaction worth $96,569.
Protara Therapeutics Inc (TARA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.40% during the next five years compared to 55.31% growth over the previous five years of trading.
Protara Therapeutics Inc (NASDAQ: TARA) Trading Performance Indicators
Here are Protara Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -2.07 in one year’s time.
Technical Analysis of Protara Therapeutics Inc (TARA)
Looking closely at Protara Therapeutics Inc (NASDAQ: TARA), its last 5-days average volume was 1.06 million, which is a jump from its year-to-date volume of 0.34 million. As of the previous 9 days, the stock’s Stochastic %D was 45.51%. Additionally, its Average True Range was 0.40.
During the past 100 days, Protara Therapeutics Inc’s (TARA) raw stochastic average was set at 13.00%, which indicates a significant decrease from 27.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.52% in the past 14 days, which was lower than the 127.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.04, while its 200-day Moving Average is $3.34. However, in the short run, Protara Therapeutics Inc’s stock first resistance to watch stands at $4.04. Second resistance stands at $4.55. The third major resistance level sits at $5.02. If the price goes on to break the first support level at $3.06, it is likely to go to the next support level at $2.59. Should the price break the second support level, the third support level stands at $2.08.
Protara Therapeutics Inc (NASDAQ: TARA) Key Stats
With a market capitalization of 129.43 million, the company has a total of 36,767K Shares Outstanding. Currently, annual sales are 0 K while annual income is -44,600 K. The company’s previous quarter sales were 0 K while its latest quarter income was -12,770 K.
